164 related articles for article (PubMed ID: 1379402)
1. CD4+, CD33-, CD13-, CD14- acute monoblastic leukaemia.
Lombard EH; Mansvelt EP
Acta Haematol; 1992; 87(3):151-2. PubMed ID: 1379402
[TBL] [Abstract][Full Text] [Related]
2. CD4 predicts nonlymphocytic lineage in acute leukemia. Insights from analysis of 125 cases using two-color flow cytometry.
Larson RS; McCurley TL
Am J Clin Pathol; 1995 Aug; 104(2):204-11. PubMed ID: 7543728
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Seshi B; Kashyap A; Bennett JM
Br J Haematol; 1992 Jul; 81(3):374-7. PubMed ID: 1382546
[TBL] [Abstract][Full Text] [Related]
4. Surface marker expression in acute myeloid leukaemia at first relapse.
Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D
Br J Haematol; 1992 May; 81(1):40-4. PubMed ID: 1381608
[TBL] [Abstract][Full Text] [Related]
5. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms.
Nakase K; Kita K; Shiku H; Tanaka I; Nasu K; Dohy H; Kyo T; Tsutani H; Kamada N
Am J Clin Pathol; 1996 Jun; 105(6):761-8. PubMed ID: 8659452
[TBL] [Abstract][Full Text] [Related]
6. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
7. Skin infiltration in acute promyelocytic leukemia.
Nagao K; Kikuchi A; Kawai Y; Kizaki M; Ikeda Y; Nishikawa T
Dermatology; 1997; 194(2):168-71. PubMed ID: 9094468
[TBL] [Abstract][Full Text] [Related]
8. Enhanced myeloid specificity of CD117 compared with CD13 and CD33.
Nomdedéu JF; Mateu R; Altès A; Llorente A; Rio C; Estivill C; López O; Ubeda J; Rubiol E
Leuk Res; 1999 Apr; 23(4):341-7. PubMed ID: 10229319
[TBL] [Abstract][Full Text] [Related]
9. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro expression of myeloid antigens on B-lineage acute lymphoblastic leukemia cells.
Hara J; Kawa-Ha K; Yumura-Yagi K; Kurahashi H; Tawa A; Ishihara S; Inoue M; Murayama N; Okada S
Leukemia; 1991 Jan; 5(1):19-25. PubMed ID: 1705635
[TBL] [Abstract][Full Text] [Related]
11. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224
[TBL] [Abstract][Full Text] [Related]
12. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Aug; 42(4):675-82. PubMed ID: 11697497
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications.
Lauria F; Raspadori D; Martinelli G; Rondelli D; Ventura MA; Farabegoli P; Tosi P; Testoni N; Visani G; Zaccaria A
Br J Haematol; 1994 Jun; 87(2):286-92. PubMed ID: 7947269
[TBL] [Abstract][Full Text] [Related]
14. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
15. CD4+ and CD56+ acute monoblastic leukemia.
Tauchi T; Ohyashiki K; Ohyashiki JH; Kawanishi Y; Kimura Y; Saito M; Nakazawa S; Kawai Y; Toyama K
Am J Hematol; 1990 Jul; 34(3):228-9. PubMed ID: 1694629
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).
García Vela JA; Martin M; Delgado I; García Alonso L; Monteserin MC; Benito L; Somolinos N; Oña F
Ann Hematol; 1999 May; 78(5):237-40. PubMed ID: 10391105
[TBL] [Abstract][Full Text] [Related]
17. Expression of monocyte/macrophage markers (CD13, CD14, CD68) on human keratinocytes in healthy and diseased skin.
Hunyadi J; Simon M; Kenderessy AS; Dobozy A
J Dermatol; 1993 Jun; 20(6):341-5. PubMed ID: 7688777
[TBL] [Abstract][Full Text] [Related]
18. [The use of monoclonal antibodies for immunologic typing and prognosis prediction in acute non-lymphoblastic leukemia].
Chen GB; Tang MH; Yang TY
Zhonghua Nei Ke Za Zhi; 1993 Jun; 32(6):405-8. PubMed ID: 7903627
[TBL] [Abstract][Full Text] [Related]
19. Circulating CD33+ large mononuclear cells contain three distinct populations with phenotype of putative antigen-presenting cells including myeloid dendritic cells and CD14+ monocytes with their CD16+ subset.
Fagnoni FF; Oliviero B; Zibera C; Gibelli N; Lozza L; Vescovini R; Sansoni P; Zambelli A; DaPrada G; Robustelli della Cuna G
Cytometry; 2001 Oct; 45(2):124-32. PubMed ID: 11590624
[TBL] [Abstract][Full Text] [Related]
20. Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia.
Woodlock TJ; Seshi B; Sham RL; Cyran EM; Bennett JM
Leuk Res; 1994 Mar; 18(3):173-81. PubMed ID: 7511190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
